Generics· August 18, 2026 · 14 min read
Generic Wakix Approved but Cannot Launch Until 2030: The Orange Book Fence
By Ran Chen#Orange Book#Generics#Generic Entry
Topic
Specialty Pharmacy
Limited distribution, hub services, fulfillment routing, REMS friction, and payer-channel coordination.
Biosimilars· August 17, 2026 · 18 min read
FDA Biosimilar Device Guidance: Presentations That Are Not Interchangeable
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Specialty· August 16, 2026 · 17 min read
Leqembi IQLIK Launches: Subcutaneous Lecanemab Moves to Specialty Pharmacy
Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability
Specialty· August 15, 2026 · 25 min read
Kidney Transplant Immunosuppression: Part B-ID Cliff, Tacrolimus, & Access
By Ran Chen#Nephrology#Medicare Part B#Coverage Access
Specialty· August 15, 2026 · 23 min read
Prostate Cancer Treatment Access Landscape: Xtandi Patent Wall & Generics
By Ran Chen#Oncology#Generic Entry#Orange Book
Specialty· August 14, 2026 · 24 min read
Multiple Myeloma Treatment Access Landscape: Generic Revlimid, Zenbexus, & Darzalex
Specialty· August 14, 2026 · 20 min read
Spinal Muscular Atrophy Treatment Access Landscape: Spinraza, Itvisma, & Evrysdi
By Ran Chen#Rare Disease#Gene Therapy#Antisense
Pricing & Access· August 13, 2026 · 20 min read
Epilepsy Treatment Access (2026): From $0.02 Generics to Zorevunersen
By Ran Chen#Antiepileptic Drugs#Antisense#Rare Disease
Specialty· August 11, 2026 · 17 min read
Myelofibrosis Treatment Access Landscape: Jakafi, Vonjo, & Selinexor
By Ran Chen#Hematology#JAK Inhibitor#Specialty Pharmacy